[SCHEDULE 13D/A] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Chirag K. Patel reports beneficial ownership of 22,180,421 shares of Amneal Pharmaceuticals Class A common stock, representing 7.1% of the class based on 314,079,309 shares outstanding. Of that total, Mr. Patel directly owns 857,980 shares and holds options for 24,977 and 28,044 shares; trusts he controls hold 21,269,420 shares. The filing states no transactions in the past 60 days and shows sole voting and dispositive power over the reported shares.

The filing also discloses an Omnibus Amendment to the Margin Loan Agreement and Pledge and Security Agreement dated August 6, 2025, which increases the collateral pledged to 19,000,000 shares and extends the loan maturity to April 29, 2028. The amended Pledge and Security Agreement is filed as an exhibit.

Insights

Financial Analyst

TL;DR: A 7.1% disclosed stake with a loan amendment that extends maturity; large pledged collateral reduces unencumbered holdings.

The reporting shows Mr. Patel as a significant holder with 22.18M shares (7.1%). Direct ownership is small relative to total beneficial ownership, with most shares held in trusts. The amendment extending the margin loan to April 29, 2028 provides financing runway, while the increase of pledged collateral to 19M shares materially changes the security posture of his position. This disclosure is meaningful for shareholder base calculations, voting influence and free float analysis.

Risk Analyst

TL;DR: Increasing pledged collateral to 19M shares raises counterparty and encumbrance risk for a material 7.1% position.

The Omnibus Amendment increasing pledged collateral to 19,000,000 shares is a notable risk indicator: a substantial portion of reported beneficial holdings are encumbered under a margin facility. While the maturity extension to April 29, 2028 reduces near-term refinancing pressure, the concentration of beneficial ownership in trusts and the scale of pledged shares could create downside risk to unencumbered supply and investor liquidity if enforcement or additional borrowing events occur.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

Amneal Pharmaceuticals, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.01

(Title of Class of Securities)

03168L105

(CUSIP Number)

Christine Krentz
4 Gatehall Drive,
Parsippany, NJ, 07054
(908) 409-6700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/06/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 03168L105

1

Name of reporting person

Patel Chirag K.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 22,180,421.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 22,180,421.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

22,180,421.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.1 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The percentage of ownership of the Class A Common Stock by the Reporting Person presented in this Statement is based on 314,079,309 shares of Class A Common Stock outstanding, as disclosed in the New Issuer's Quarterly Report on Form 10-Q, filed on August 7, 2025.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Class A Common Stock, par value $0.01
(b)	Name of Issuer: Amneal Pharmaceuticals, Inc.
(c)	Address of Issuer's Principal Executive Offices: 400 Crossing Blvd, Bridgewater, NEW JERSEY , 08807.
Item 4.	Purpose of Transaction
	This Amendment No. 6 to Schedule 13D (this "Amendment No. 6") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 6, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the New Issuer. Capitalized terms used but not defined in this Amendment No. 6 shall have the meanings set forth in the Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(b)	The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Class A Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 314,079,309 shares of Class A Common Stock outstanding, as disclosed in the New Issuer's Quarterly Report on Form 10-Q, filed on August 7, 2025: Reporting Person - Chirag Patel Amount Beneficially Owned - 22,180,421 Percent of Class - 7.1 Sole power to vote or to direct the vote - 22,180,421 Shared power to vote or to direct the vote - 0 Sole power to dispose or to direct the disposition - 22,180,421 Shared power to dispose or to direct the disposition - 0 The Reporting Person owns directly (i) 857,980 shares of Class A Common Stock, (ii) 24,977 shares of Class A Common Stock issuable upon exercise of options exercisable for $15.01 per share, which expire on May 7, 2028 and (iii) 28,044 shares of Class A Common Stock issuable upon exercise of options exercisable for $14.05 per share, which expire on May 6, 2029; and may be deemed to beneficially own 21,269,420 shares of Class A Common Stock held of record by trusts controlled by the Reporting Person.
(c)	During the past 60 days, the Reporting Person has not effected any transactions in the Class A Common Stock.
(d)	None.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Item 6 of the Schedule 13D is hereby amended and supplemented by adding the following information. On August 6, 2025, the Borrowers entered into an Omnibus Amendment Agreement (the "Amendment") to the Margin Loan Agreement with UBS, and the Pledge and Security Agreement, dated as of October 29, 2024, by and between the Borrowers and UBS (the "Security Agreement"). In connection therewith, the Borrowers and UBS agreed to increase the Collateral pledged pursuant to the Security Agreement to 19,000,000 shares of Class A Common Stock, and extend the maturity date for the obligations of the Borrowers under the Margin Loan Agreement to April 29, 2028. A copy of the Security Agreement, as modified by the Amendment, is attached as an Exhibit to this Schedule 13D, and is incorporated herein by reference. Except as set forth herein, the Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.
Item 7.	Material to be Filed as Exhibits.
	Pledge and Security Agreement, dated as of October 29, 2024, by and among each of the Borrowers, UBS and UBS Financial Services Inc., as amended by the Omnibus Amendment Agreement, dated as of August 6, 2025.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Patel Chirag K.

Signature:	Chirag K. Patel
Name/Title:	Patel Chirag K.
Date:	08/08/2025

FAQ

How many AMRX shares does Chirag K. Patel beneficially own?

The filing reports 22,180,421 shares beneficially owned, representing 7.1% of Class A common stock based on 314,079,309 shares outstanding.

What portion of Patel's AMRX holdings are pledged as collateral?

The Omnibus Amendment increases collateral pledged under the Security Agreement to 19,000,000 shares.

How are Patel's AMRX holdings structured between direct ownership and trusts?

Mr. Patel directly owns 857,980 shares and options for 24,977 and 28,044 shares; trusts he controls hold 21,269,420 shares.

What change did the margin loan amendment make?

On August 6, 2025, the Borrowers and UBS amended the margin loan and Security Agreement to increase pledged collateral to 19,000,000 shares and extend the loan maturity to April 29, 2028.

Has Patel traded AMRX recently?

The filing states that during the past 60 days the Reporting Person has not effected any transactions in Class A common stock.